Skip to main content


Development and evaluation of the oligonucleotide ligation assay (OLA) for the detection of drug resistance mutations in HIV-2 patients on antiretroviral therapy

Article metrics


The naturally resistance of HIV-2 to non-nucleoside reverse transcriptase inhibitors and T-20, as well as its reduced susceptibility to some protease inhibitors makes the nucleoside reverse transcriptase inhibitors (NRTI) crucial in HIV-2 therapy. Hence, early detection of resistance mutations to NRTI is important to explain treatment failures and to guide therapy.

Materials and methods

HIV-2 OLA was developed for the Q151M and M184V mutations using a set of 3 oligonucleotide probes for each mutation. 90 HIV-2 samples from Guinea Bissau, the Gambia and Sweden were amplified, sequenced and evaluated in OLA.


OLA sensitivity was 100% for Q151M and 98% for M184V. Concordance between sequencing and OLA was 99% and 97% for the Q151M and M184V mutations respectively.


OLA was successfully developed for major HIV-2 mutations. Its ease-of-use, economical nature and high concordance with sequencing makes it more appropriate for use in resource-poor settings.

Author information

Correspondence to Sabelle Jallow.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article


  • Drug Resistance
  • Nucleoside
  • Treatment Failure
  • Oligonucleotide Probe
  • Resistance Mutation